Zolbetuximab
- Product Name
- Zolbetuximab
- CAS No.
- 1496553-00-4
- Chemical Name
- Zolbetuximab
- Synonyms
- IMAB362;Zolbetuximab;Zolbetuximab (IMAB362);Research Grade Zolbetuximab;Zolbetuximab (anti-CLDN18.2);Research Grade Zolbetuximab (DHF19801)
- CBNumber
- CB08081041
- Formula Weight
- 0
- MOL File
- Mol file
Zolbetuximab Property
- form
- Liquid
- color
- Colorless to light yellow
Zolbetuximab Chemical Properties,Usage,Production
Uses
Zolbetuximab (development code IMAB362) is an experimental monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors.
Mechanism of action
Zolbetuximab is the first drug developed against the target of Claudin18.2. It is a chimeric IgG1 monoclonal antibody that specifically binds to Claudin18.2 on the surface of tumor cells, thereby triggering antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), apoptosis and inhibition of cell proliferation.
in vivo
Zolbetuximab (200 μg, i.v.) alone and in combination with Gemcitabine (HY-17026) (50 mg/kg, i.p.) exhibits antitumor activity in mouse BxPC-3-CLDN18.2 xenograft models[2].
Zolbetuximab (5.7 mg/kg, i.p., three times per week for five weeks) inhibits tumor growth in SNU-620 cells xenograft model[3].
| Animal Model: | mouse BxPC-3-CLDN18.2, MIA PaCa-2-CLDN18.2 xenograft model[2] |
| Dosage: | 200 μg alone or with 50 mg/kg Gemcitabine |
| Administration: | i.v.; i.p. (Gemcitabine) |
| Result: | Inhibited tumor growth in two models, and prevented lung metastasis formation. Prolonged survival time, and lowered fractions of CLDN18.2+ cells in MIA PaCa-2-CLDN18.2 xenograft. |
Zolbetuximab Preparation Products And Raw materials
Raw materials
Preparation Products
Zolbetuximab Suppliers
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32435
- Advantage
- 58